Anti-IL5 Therapies for Severe Eosinophilic Asthma: Literature Review and Practical Insights

References

• Trevor JL, Chipps BE. Severe asthma in primary care: identification and management. Am J Med. 2018;131(5):484. (). doi:10.1016/j.amjmed.2017.12.03429355509
   PubMed Web of Science ®Google Scholar
• Luskin AT, Chipps BE, Rasouliyan L, et al. Impact of asthma exacerbations and asthma triggers on asthma-related quality of life in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol Pract. 2014;2(5):544e552:e541–e542. doi:10.1016/j.jaip.2014.02.011
   PubMed Web of Science ®Google Scholar
• Bleecker ER, Menzies-Gow AN, Price DB, et al. Systematic literature review of systemic corticosteroid use for asthma management. Am J Respir Crit Care Med. 2020;201(3):276–293. doi:10.1164/rccm.201904-0903SO31525297
   PubMed Web of Science ®Google Scholar
• Uhm TG, Kim BS, Chung IY. Eosinophil development, regulation of eosinophil-specific genes, and role of eosinophils in the pathogenesis of asthma. Allergy Asthma Immunol Res. 2012;4(2):68–79. doi:10.4168/aair.2012.4.2.6822379601
   PubMed Web of Science ®Google Scholar
• Takatsu K, Nakajima H. IL-5 and eosinophilia. Curr Opin Immunol. 2008;20:288–294. doi:10.1016/j.coi.2008.04.00118511250
   PubMed Web of Science ®Google Scholar
• Kouro T, Takatsu K. IL-5- and eosinophil-mediated inflammation: from discovery to therapy. Int Immunol. 2009;21(12):1303–1309. doi:10.1093/intimm/dxp10219819937
   PubMed Web of Science ®Google Scholar
• Licona-Limon P, Kim LK, Palm NW, et al. TH2, allergy and group 2 innate lymphoid cells. Nat Immunol. 2013;14:536–542. doi:10.1038/ni.261723685824
   PubMed Web of Science ®Google Scholar
• Smith SG, Chen R, Kjarsgaard M, et al. Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. J Allergy Clin Immunol. 2016;137:75–86.e78. doi:10.1016/j.jaci.2015.05.03726194544
   PubMed Web of Science ®Google Scholar
• Dent LA, Strath M, Mellor AL, Sanderson CJ. Eosinophilia in transgenic mice expressing interleukin 5. J Exp Med. 1990;172:1425e31. doi:10.1084/jem.172.5.14252230651
   PubMed Web of Science ®Google Scholar
• Prakash Babu S, Chen YK, Bonne-Annee S, et al. Dysregulation of interleukin 5 expression in familial eosinophilia. Allergy. 2017;72(9):1338e45. doi:10.1111/all.1314628226398
   PubMed Web of Science ®Google Scholar
• Adachi T, Alam R. The mechanism of IL-5 signal transduction. Am J Physiol. 1998;275:C623e33. doi:10.1152/ajpcell.1998.275.3.C6239730944
   PubMed Web of Science ®Google Scholar
• Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol. 2006;24:147–174. doi:10.1146/annurev.immunol.24.021605.09072016551246
   PubMed Web of Science ®Google Scholar
• Travers J, Rothenberg ME. Eosinophils in mucosal immune responses. Mucosal Immunol. 2015;8(3):464–475. doi:10.1038/mi.2015.225807184
   PubMed Web of Science ®Google Scholar
• Chu VT, Beller A, Rausch S, et al. Eosinophils promote generation and maintenance of immunoglobulin-A-expressing plasma cells and contribute to gut immune homeostasis. Immunity. 2014;40(4):582–593. doi:10.1016/j.immuni.2014.02.01424745334
   PubMed Web of Science ®Google Scholar
• Jung Y, Wen T, Mingler MK, et al. IL-1β in eosinophil-mediated small intestinal homeostasis and IgA production. Mucosal Immunol. 2015;8(4):930–942. doi:10.1038/mi.2014.12325563499
   PubMed Web of Science ®Google Scholar
• Mesnil C, Raulier S, Paulissen G, et al. Lung-resident eosinophils represent a distinct regulatory eosinophil subset. J Clin Invest. 2016;126(9):3279–3295. doi:10.1172/JCI8566427548519
   PubMed Web of Science ®Google Scholar
• Salter BM, Sehmi R. Hematopoietic processes in eosinophilic asthma. Chest. 2017;152(2):410–416. doi:10.1016/j.chest.2017.01.02128130045
   PubMed Web of Science ®Google Scholar
• Wu CA, Peluso JJ, Zhu L, et al. Bronchial epithelial cells produce IL-5: implications for local immune responses in the airways. Cell Immunol. 2010;264(1):32–41. doi:10.1016/j.cellimm.2010.04.00820494340
   PubMed Web of Science ®Google Scholar
• Zia-Amirhosseini P, Minthorn E, Benincosa LJ, et al. Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys. J Pharmacol Exp Ther. 1999;291(3):1060–1067.10565825
   PubMed Web of Science ®Google Scholar
• Hart TK, Cook RM, Zia-Amirhosseini P, et al. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol. 2001;108(2):250–257. doi:10.1067/mai.2001.11657611496242
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. doi:10.1056/NEJMoa140329025199059
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659. doi:10.1016/S0140-6736(12)60988-X22901886
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197. doi:10.1056/NEJMoa140329125199060
   PubMed Web of Science ®Google Scholar
• Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390–400. doi:10.1016/S2213-2600(17)30125-X28395936
   PubMed Web of Science ®Google Scholar
• Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4(7):549–556. doi:10.1016/S2213-2600(16)30031-527177493
   PubMed Web of Science ®Google Scholar
• Lugogo N, Domingo C, Chanez P, et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clin Ther. 2016;38(9):2058–2070.e1. doi:10.1016/j.clinthera.2016.07.01027553751
   PubMed Web of Science ®Google Scholar
• Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019;143(5):1742–1751.e7. doi:10.1016/j.jaci.2018.09.03330359681
   PubMed Web of Science ®Google Scholar
• Busse W, Chupp G, Nagase H, et al. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: indirect treatment comparison. J Allergy Clin Immunol. 2019;143(1):190–200.e20. doi:10.1016/j.jaci.2018.08.03130205189
   PubMed Web of Science ®Google Scholar
• Kallieri M, Zervas E, Katsoulis K, et al. Mepolizumab in severe eosinophilic asthma: a 2-year follow-up in specialized asthma clinics in Greece: an interim analysis. Int Arch Allergy Immunol. 2020;181(8):613–617. doi:10.1159/00050855932570256
   PubMed Web of Science ®Google Scholar
• Carpagnano GE, Pelaia C, D’Amato M, et al. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy. Ther Adv Respir Dis. 2020;14:1753466620929231. doi:10.1177/175346662092923132482128
   PubMed Web of Science ®Google Scholar
• Pelaia C, Crimi C, Pelaia G, et al. Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype. Clin Exp Allergy. 2020;50(7):780–788. doi:10.1111/cea.1361332347992
   PubMed Web of Science ®Google Scholar
• European Medicines Agency - European Public Assessment Report (EPAR) for Nucala (mepolizumab). https://www.ema.europa.eu/en/medicines/human/EPAR/nucala. Accessed 712 2020.
   Google Scholar
• Mukherjee M, Aleman Paramo F, et al. Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab. Am J Respir Crit Care Med. 2018;197(1):38–46. doi:10.1164/rccm.201707-1323OC28915080
   PubMed Web of Science ®Google Scholar
• Vultaggio A, Nencini F, Bormioli S, et al. Low-dose mepolizumab effectiveness in patients suffering from eosinophilic granulomatosis with polyangiitis. Allergy Asthma Immunol Res. 2020;12(5):885–893. doi:10.4168/aair.2020.12.5.88532638567
   PubMed Web of Science ®Google Scholar
• Menzella F, Lusuardi M, Galeone C, et al. The clinical profile of benralizumab in the management of severe eosinophilic asthma. Ther Adv Respir Dis. 2016;10(6):534–548. doi:10.1177/175346581666765927612492
   PubMed Web of Science ®Google Scholar
• Pelaia C, Calabrese C, Vatrella A, et al. Benralizumab: from the basic mechanism of action to the potential use in the biological therapy of severe eosinophilic asthma. Biomed Res Int. 2018;2018:4839230. doi:10.1155/2018/483923029862274
   PubMed Web of Science ®Google Scholar
• Tai PC, Sun L, Spry CJ. Effects of IL-5, granulocyte/macrophage colony-stimulating factor (GM-CSF) and IL-3 on the survival of human blood eosinophils in vitro. Clin Exp Immunol. 1991;85(2):312–316. doi:10.1111/j.1365-2249.1991.tb05725.x1864012
   PubMed Web of Science ®Google Scholar
• Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013;132(5):1086–1096.e5. doi:10.1016/j.jaci.2013.05.02023866823
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127. doi:10.1016/S0140-6736(16)31324-127609408
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141. doi:10.1016/S0140-6736(16)31322-827609406
   PubMed Web of Science ®Google Scholar
• Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448–2458. doi:10.1056/NEJMoa170350128530840
   PubMed Web of Science ®Google Scholar
• Busse WW, Bleecker ER, FitzGerald JM, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019;7(1):46–59. doi:10.1016/S2213-2600(18)30406-530416083
   PubMed Web of Science ®Google Scholar
• Menzella F, Latorre M, Ruggiero P, Bagnasco D, Heffler E. Reduction of oral corticosteroids in patients with severe eosinophilic asthma treated with Benralizumab: could it represent a marker of treatment efficacy? Expert Opin Biol Ther. 2019;19(7):601–606. doi:10.1080/14712598.2019.161336731033373
   PubMed Web of Science ®Google Scholar
• Caminati M, Menzella F, Guidolin L, et al. Targeting eosinophils: severe asthma and beyond. Drugs Context. 2019;8:212587. doi:10.7573/dic.21258731391853
   PubMedGoogle Scholar
• Bleecker ER, Wechsler ME, FitzGerald JM, et al. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J. 2018;52(4):1800936. doi:10.1183/13993003.00936-201830139780
   PubMed Web of Science ®Google Scholar
• Chipps BE, Newbold P, Hirsch I. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2018;120(5):504–511.e4. doi:10.1016/j.anai.2018.01.03029409951
   PubMed Web of Science ®Google Scholar
• Padilla-Galo A, Levy-Abitbol R, Olveira C, et al. Real-life experience with benralizumab during 6 months. BMC Pulm Med. 2020;20(1):184. doi:10.1186/s12890-020-01220-932600318
   PubMed Web of Science ®Google Scholar
• Pelaia C, Busceti MT, Crimi C, et al. Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma. Biomed Pharmacother. 2020;129:110444. doi:10.1016/j.biopha.2020.11044432593131
   PubMed Web of Science ®Google Scholar
• Mavissakalian M, Brady S. The current state of biologic therapies for treatment of refractory asthma. Clin Rev Allergy Immunol. 2020. doi:10.1007/s12016-020-08776-8
   Web of Science ®Google Scholar
• Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184(10):1125–1132. doi:10.1164/rccm.201103-0396OC21852542
   PubMed Web of Science ®Google Scholar
• Sahota J, Robinson DS. Update on new biologics for intractable eosinophilic asthma: impact of reslizumab. Drug Des Devel Ther. 2018;12:1173–1181. doi:10.2147/DDDT.S109489
   PubMed Web of Science ®Google Scholar
• Weinstein SF, Katial RK, Bardin P, et al. Effects of reslizumab on asthma outcomes in a subgroup of eosinophilic asthma patients with self-reported chronic rhinosinusitis with nasal polyps. j allergy clin immunol pract. 2019;7(2):589–596.e3. doi:10.1016/j.jaip.2018.08.02130193936
   PubMed Web of Science ®Google Scholar
• Ibrahim H, O’Sullivan R, Casey D, et al. The effectiveness of Reslizumab in severe asthma treatment: a real-world experience. Respir Res. 2019;20(1):289. doi:10.1186/s12931-019-1251-331861993
   PubMed Web of Science ®Google Scholar
• Bao K, Reinhardt RL. The differential expression of IL-4 and IL-13 and its impact on type-2 immunity. Cytokine. 2015;75(1):25–37. doi:10.1016/j.cyto.2015.05.00826073683
   PubMed Web of Science ®Google Scholar
• Menzella F, Bertolini F, Biava M, et al. Severe refractory asthma: current treatment options and ongoing research. Drugs Context. 2018;7:212561. doi:10.7573/dic.21256130534175
   PubMedGoogle Scholar
• Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–2496. doi:10.1056/NEJMoa180409229782217
   PubMed Web of Science ®Google Scholar
• Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–2485. doi:10.1056/NEJMoa180409329782224
   PubMed Web of Science ®Google Scholar
• Corren J, Castro M, O’Riordan T, et al. Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma. J Allergy Clin Immunol Pract. 2020;8(2):516–526. doi:10.1016/j.jaip.2019.08.05031521831
   PubMed Web of Science ®Google Scholar
• Maspero JF, Katelaris CH, Busse WW, et al. Dupilumab efficacy in uncontrolled, moderate-to-severe asthma with self-reported chronic rhinosinusitis. J Allergy Clin Immunol Pract. 2020;8(2):527–539.e9. doi:10.1016/j.jaip.2019.07.01631351189
   PubMed Web of Science ®Google Scholar
• Sanofi-Aventis U.S. LLC and Regeneron Pharmaceuticals Inc. Dupixent (dupilumab) injection: US prescribing information. 2019 Available from: http://www.accessdata.fda.gov. Accessed 719, 2020.
   Google Scholar
• Dupin C, Belhadi D, Guilleminault L, et al. Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort. Clin Exp Allergy. 2020;50(7):789–798. doi:10.1111/cea.1361432469092
   PubMed Web of Science ®Google Scholar
• Katsaounou P, Buhl R, Brusselle G, et al. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma. Respir Med. 2019;150:51–62. doi:10.1016/j.rmed.2019.02.00330961951
   PubMed Web of Science ®Google Scholar
• MacGlashan DW Jr, Bochner BS, Adelman DC, et al. Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997;1583:1438–1445.
   Google Scholar
• Mitchell PD, El-Gammal AI, O’Byrne PM. Anti-IgE and biologic approaches for the treatment of asthma. Handb Exp Pharmacol. 2017;237:131–152.27864676
   PubMedGoogle Scholar
• Ledford D, Busse W, Trzaskoma B, et al. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. J Allergy Clin Immunol. 2017;140(1):162–169.e2. doi:10.1016/j.jaci.2016.08.05427826098
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest. 2011;139(1):28–35. doi:10.1378/chest.10-119420688929
   PubMed Web of Science ®Google Scholar
• Menzella F, Piro R, Facciolongo N, et al. Long-term benefits of omalizumab in a patient with severe non-allergic asthma. Allergy Asthma Clin Immunol. 2011;7(1):9. doi:10.1186/1710-1492-7-921609447
   PubMed Web of Science ®Google Scholar
• Forester JP, Calabria CW. Local production of IgE in the respiratory mucosa and the concept of entopy: does allergy exist in nonallergic rhinitis? Ann Allergy Asthma Immunol. 2010;105(4):249–255. doi:10.1016/j.anai.2010.02.00120934624
   PubMed Web of Science ®Google Scholar
• Teach SJ, Gill MA, Togias A, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol. 2015;136(6):1476–1485. doi:10.1016/j.jaci.2015.09.00826518090
   PubMed Web of Science ®Google Scholar
• Maggi L, Rossettini B, Montaini G, et al. Omalizumab dampens type 2 inflammation in a group of long-term treated asthma patients and detaches IgE from FcεRI. Eur J Immunol. 2018;48(12):2005–2014. doi:10.1002/eji.20184766830252930
   PubMed Web of Science ®Google Scholar
• Hanania NA, Wenzel S, Rosén K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187(8):804–811. doi:10.1164/rccm.201208-1414OC23471469
   PubMed Web of Science ®Google Scholar
• Pelaia C, Calabrese C, Terracciano R, de Blasio F, Vatrella A, Pelaia G. Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness. Ther Adv Respir Dis. 2018;12:1753466618810192. doi:10.1177/175346661881019230400762
   PubMed Web of Science ®Google Scholar
• Wagener AH, de Nijs SB, Lutter R, et al. External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. Thorax. 2015;70(2):115–120. doi:10.1136/thoraxjnl-2014-20563425422384
   PubMed Web of Science ®Google Scholar
• Menzella F, Galeone C, Formisano D, et al. Real-life efficacy of omalizumab after 9 years of follow-up. Allergy Asthma Immunol Res. 2017;9(4):368–372. doi:10.4168/aair.2017.9.4.36828497924
   PubMed Web of Science ®Google Scholar
• Nachef Z, Krishnan A, Mashtare T, Zhuang T, Mador MJ. Omalizumab versus Mepolizumab as add-on therapy in asthma patients not well controlled on at least an inhaled corticosteroid: a network meta-analysis. J Asthma. 2017;1–12.
   Web of Science ®Google Scholar
• Albers FC, Müllerová H, Gunsoy NB, et al. Biologic treatment eligibility for real-world patients with severe asthma: the IDEAL study. J Asthma. 2018;55(2):152–160. doi:10.1080/02770903.2017.132261128622052
   PubMed Web of Science ®Google Scholar
• Magnan A, Bourdin A, Prazma CM, et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. Allergy. 2016;71(9):1335–1344. doi:10.1111/all.1291427087007
   PubMed Web of Science ®Google Scholar
• Shaw DE, Sousa AR, Fowler SJ, et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J. 2015;46(5):1308–1321. doi:10.1183/13993003.00779-201526357963
   PubMed Web of Science ®Google Scholar
• Leckie MJ, Ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000;356(9248):2144–2148. doi:10.1016/S0140-6736(00)03496-611191542
   PubMed Web of Science ®Google Scholar
• Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007;176(11):1062–1071. doi:10.1164/rccm.200701-085OC17872493
   PubMed Web of Science ®Google Scholar
• Bakakos A, Loukides S, Bakakos P. Severe Eosinophilic Asthma. J Clin Med. 2019;8(9):1375. doi:10.3390/jcm8091375
   PubMed Web of Science ®Google Scholar
• Bousquet J, Brusselle G, Buhl R, et al. Care pathways for the selection of a biologic in severe asthma. Eur Respir J. 2017;50:1701782. doi:10.1183/13993003.01782-201729217605
   PubMed Web of Science ®Google Scholar
• Caminati M, Senna G, Stefanizzi G, et al. Drop-out rate among patients treated with omalizumab for severe asthma: literature review and real-life experience. BMC Pulm Med. 2016;16(1):128. doi:10.1186/s12890-016-0290-527562427
   PubMed Web of Science ®Google Scholar
• Tran TN, Khatry DB, Ke X, Ward CK, Gossage D. High blood eosinophil count is associated with more frequent asthma attacks in asthma patients. Ann Allergy Asthma Immunol. 2014;113:19–24. doi:10.1016/j.anai.2014.04.01124846699
   PubMed Web of Science ®Google Scholar
• Yancey SW, Keene ON, Albers FC, et al. Biomarkers for severe eosinophilic asthma. J Allergy Clin Immunol. 2017;140:1509–1518. doi:10.1016/j.jaci.2017.10.00529221581
   PubMed Web of Science ®Google Scholar
• Price DB, Rigazio A, Campbell JD, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med. 2015;3:849–858. doi:10.1016/S2213-2600(15)00367-726493938
   PubMed Web of Science ®Google Scholar
• Zeiger RS, Schatz M, Li Q, et al. High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma. J Allergy Clin Immunol Pract. 2014;2:741–750. doi:10.1016/j.jaip.2014.06.00525439366
   PubMed Web of Science ®Google Scholar
• Katz LE, Gleich GJ, Hartley BF, et al. Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma. Ann Am Thorac Soc. 2014;11:531–536. doi:10.1513/AnnalsATS.201310-354OC24606022
   PubMedGoogle Scholar
• Bjermer L, Lemiere C, Maspero J, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016;150:789–798. doi:10.1016/j.chest.2016.03.03227056586
   PubMed Web of Science ®Google Scholar
• Corren J, Weinstein S, Janka L, et al. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150:799–810. doi:10.1016/j.chest.2016.03.01827018175
   PubMed Web of Science ®Google Scholar
• Crespo A, Giner J, Torrejón M, et al. Clinical and inflammatory features of asthma with dissociation between fractional exhaled nitric oxide and eosinophils in induced sputum. J Asthma. 2016;53:459–464. doi:10.3109/02770903.2015.111608626785727
   PubMed Web of Science ®Google Scholar
• Calciano L, Portas L, Corsico AG, et al. Biomarkers related to respiratory symptoms and lung function in adults with asthma. J Breath Res. 2018;12:026012. doi:10.1088/1752-7163/aa9c8629167414
   PubMed Web of Science ®Google Scholar
• McNicholl DM, Heaney LG. Omalizumab: the evidence for its place in the treatment of allergic asthma. Core Evid. 2008;3:55–66. doi:10.3355/ce.2008.01220694084
   PubMedGoogle Scholar
• Ito K, Chung KF, Adcock IM. Update on glucocorticoid action and resistance. J Allergy Clin Immunol. 2006;117:522–543. doi:10.1016/j.jaci.2006.01.03216522450
   PubMed Web of Science ®Google Scholar
• Normansell R, Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;CD003559.24414989
   PubMed Web of Science ®Google Scholar
• Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18:254–261. doi:10.1183/09031936.01.0009210111529281
   PubMed Web of Science ®Google Scholar